Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Otelixizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Otelixizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Otelixizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Otelixizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Otelixizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Otelixizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Otelixizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Otelixizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Otelixizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Otelixizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Otelixizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Otelixizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Otelixizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Otelixizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Otelixizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Otelixizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Otelixizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Otelixizumab. |
| Equol | Equol may increase the thrombogenic activities of Otelixizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Otelixizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Otelixizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Otelixizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Otelixizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Otelixizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Otelixizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Otelixizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Otelixizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Otelixizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Otelixizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Otelixizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Otelixizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Otelixizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Otelixizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Otelixizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Otelixizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Otelixizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Otelixizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Otelixizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Otelixizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Otelixizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Otelixizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Otelixizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Otelixizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Otelixizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Otelixizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Otelixizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Otelixizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Otelixizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Otelixizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Otelixizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Otelixizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Otelixizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Otelixizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Otelixizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Otelixizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Otelixizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Otelixizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Otelixizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Otelixizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Otelixizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Otelixizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Otelixizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Otelixizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Otelixizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Otelixizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Otelixizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Otelixizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Otelixizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Otelixizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Otelixizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Otelixizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Otelixizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Otelixizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Otelixizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Otelixizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Otelixizumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Canakinumab. |